drugset / Trial / NCT04771351

Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Hospitalized Adults With COVID-19

NCT04771351 ↗

Phase 2 Withdrawn Sorrento Therapeutics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a placebo-controlled study to investigate the safety and efficacy of a single injection of COVI-AMG in inpatient adults with COVID-19.

Timeline

Start
2021-04
Primary completion
2021-08
Completion
2021-10

Outcome

Outcome not reported

Stopped: “A different study will be conducted.”

Drugs

EvaluationDrugModalityDoseRoute
Subject PLUTAVIMAB Monoclonal antibody 100 mg Intravenous
Subject PLUTAVIMAB Monoclonal antibody 200 mg Intravenous

Indications